Bibliographic Details
| Title: |
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for ALS. |
| Authors: |
Miller, T.1 miller.t@wustl.edu, Cudkowicz, M.2, Shaw, P. J.3, Andersen, P. M.4, Atassi, N.2, Bucelli, R. C.1, Genge, A.5, Glass, J.6, Ladha, S.7, Ludolph, A. L.8, Maragakis, N. J.9, McDermott, C. J.3, Pestronk, A.1, Ravits, J.10, Salachas, F.11, Trudell, R.12, Van Damme, P.13, Zinman, L.14, Bennett, C. F.15, Lane, R.15 |
| Source: |
New England Journal of Medicine. 7/9/2020, Vol. 383 Issue 2, p109-119. 11p. |
| Database: |
Academic Search Ultimate |
